Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RICE Protocol for Relapsed/Refractory CD20+ Lymphoma
NCT00005631Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 1999
- Primary completion
- Nov 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL), Anaplastic Large Cell Lymphoma (ALCL) and lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete Response Rate. Started Nov 1999; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Anaplastic Large Cell Lymphoma (ALCL)lymphoma
Beyond the preview
Go deeper on NCT00005631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005631.